AssayMetrics and Cambridge Research Biochemicals Collaborate
News Oct 08, 2012
AssayMetrics Ltd has announced collaboration with Cambridge Research Biochemicals Ltd, the UK’s most established peptide and antibody company.
Fluorescence Lifetime is a new and assay technology used in the biochemical screening of new drugs in High Throughput Screening and compound characterization roles in the pharmaceutical industry.
The collaboration involves Cambridge Research Biochemicals making key peptide substrates labelled with AssayMetrics’ Fluorescence Lifetime dyes.
The peptides are used to screen novel drugs in equipment such as AssayMetrics’ Fluospec® FL reader and are employed in assays involving kinases, proteases, protein:protein interactions and other target enzyme systems.
The collaboration brings together two companies leading their respective fields to be able to offer solutions to the pharmaceutical industry enabling faster, more efficient and cheaper drug discovery and development, thereby improving the effectiveness of pharmaceutical R&D.
Dr Pierre Graves, MD of AssayMetrics Ltd commented, “This is exciting news as Cambridge Research Biochemicals have considerable expertise in making the type of complex peptides needed for innovative discovery.”
Emily Humphrys, Commercial Director of Cambridge Research Biochemicals was equally positive: “This technology has so much potential that we are really pleased to be collaborating with AssayMetrics at this early stage.”
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Progressive Kidney Disease: New Compound Restores Kidney FunctionNews
A team led by researchers describe a new approach to prevent death in these essential kidney cells. Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function.READ MORE
3D Mini Brains Accelerate Drug Screening and Brain Function ResearchNews
Houston Methodist neuroscientist Robert Krencik, Ph.D., and his team have developed a new system to reduce the time it takes to grow these brain models, which will give them the ability to screen drugs and study what’s behind disease-causing mutations more quickly.READ MORE